Sjögren's syndrome (SS) is characterized by autoimmune activation and loss of function in the salivary glands. Recent studies reported that bone morphogenetic protein 6 (BMP6), which is a member of transforming growth factor beta (TGF-β) superfamily, was highly expressed in SS patients. To investigate the role of BMP6 in SS, we treated the salivary gland-derived mesenchymal stem cells (SGMSCs) with BMP6 and found that BMP6 could impair immunomodulatory properties of normal SGMSCs by downregulating the Prostaglandin E2 synthase through DNA-binding protein inhibitor-1. Neutralizing the BMP6 could significantly restore the SGMSC's immunoregulatory function in vitro and delay the SS disease activity in vivo. In conclusion, BMP6 could not only affect the secreting function of epithelial cells in the salivary gland but also influence the immunomodulatory properties of SGMSCs, which may trigger or enhance the autoimmune reflection in SS.
LaiZ, YinH, Cabrera-PérezJ, GuimaroMC, AfioneS, MichaelDG, GlentonP, PatelA, SwaimWD, et al. (2016). Aquaporin gene therapy corrects Sjögren's syndrome phenotype in mice. Proc Natl Acad Sci U S A, 113:5694–5699.
3.
VerstappenGM, MeinersPM, CornethOBJ, VisserA, ArendsS, AbdulahadWH, HendriksRW, VissinkA, KroeseFGM and BootsmaH. (2017). Abatacept attenuates T follicular helper-cell-dependent B-cell hyperactivity in primary Sjogren's syndrome. Arthritis Rheumatol, 69:1850–1861.
4.
RenG, ZhangL, ZhaoX, XuG, ZhangY, RobertsAI, ZhaoRC and ShiY. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2:141–150.
5.
WangY, ChenX, CaoW and ShiY. (2014). Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol, 15:1009–1016.
WangSQ, WangYX and HuaH. (2017). Characteristics of labial gland mesenchymal stem cells of healthy individuals and patients with Sjogren's syndrome: a preliminary study. Stem Cells Dev, 26:1171–1185.
8.
YinH, Cabrera-PerezJ, LaiZ, MichaelD, WellerM, SwaimWD, LiuX, CatalánMA, RochaEM, et al. (2013). Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjogren's syndrome and in mice. Arthritis Rheum, 65:3228–3238.
9.
VitaliC, BombardieriS, JonssonR, MoutsopoulosHM, AlexanderEL, CarsonsSE, DanielsTE, FoxPC, FoxRI, et al.. (2002). Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis, 61:554–558.
10.
RotterN, OderJ, SchlenkeP, LindnerU, BöhrnsenF, KramerJ, RohwedelJ, HussR, BrandauS, WollenbergB and LangS. (2008). Isolation and characterization of adult stem cells from human salivary glands. Stem Cells Dev, 17:509–518.
11.
LimJY, YiT, LeeS, KimJ, KimSN, SongSU and KimYM. (2015). Establishment and characterization of mesenchymal stem cell-like clonal stem cells from mouse salivary glands. Tissue Eng C Methods, 21:447–457.
AndriopoulosBJr., CorradiniE, XiaY, FaasseSA, ChenS, GrgurevicL, KnutsonMD, PietrangeloA, VukicevicS, LinHY and BabittJL. (2009). BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet, 41:482–487.
14.
KorchynskyiO and ten DijkeP. (2002). Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem, 277:4883–4891.
15.
MeiselR, ZibertA, LaryeaM, GöbelU, DäubenerW and DillooD. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103:4619–4621.
16.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
17.
ChenX, ArmstrongMA and LiG. (2006). Mesenchymal stem cells in immunoregulation. Immunol Cell Biol, 84:413–421.
18.
Castro-ManrrezaME and MontesinosJJ. (2015). Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res, 2015:394917.
19.
FanL, YuZ, LiJ, DangX and WangK. (2014). Immunoregulation effects of bone marrow-derived mesenchymal stem cells in xenogeneic acellular nerve grafts transplant. Cell Mol Neurobiol, 34:999–1010.
20.
GaoF, ChiuSM, MotanDA, ZhangZ, ChenL, JiHL, TseHF, FuQL and LianQ. (2016). Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis, 7:e2062.
21.
SunL, AkiyamaK, ZhangH, YamazaT, HouY, ZhaoS, XuT, LeA and ShiS. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells, 27:1421–1432.
EnglishK, RyanJM, TobinL, MurphyMJ, BarryFP and MahonBP. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol, 156:149–160.
24.
SreeramkumarV, FresnoM and CuestaN. (2012). Prostaglandin E2 and T cells: friends or foes?. Immunol Cell Biol, 90:579–586.
25.
WalkerC, KristensenF, BettensF and deWeckAL. (1983). Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol, 130:1770–1773.
26.
WiemerAJ, HegdeS, GumperzJE and HuttenlocherA. (2011). A live imaging cell motility screen identifies prostaglandin E2 as a T cell stop signal antagonist. J Immunol, 187:3663–3670.
27.
BetzM and FoxBS. (1991). Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol, 146:108–113.
28.
SnijdewintFG, KalińskiP, WierengaEA, BosJD and KapsenbergML. (1993). Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol, 150:5321–5329.
29.
MahicM, YaqubS, JohanssonCC, TaskénK and AandahlEM. (2006). FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol, 177:246–254.
30.
MannieMD, PrevostKD and MarinakisCA. (1995). Prostaglandin E2 promotes the induction of anergy during T helper cell recognition of myelin basic protein. Cell Immunol, 160:132–138.
31.
FrischBJ, PorterRL, GigliottiBJ, Olm-ShipmanAJ, WeberJM, O'KeefeRJ, JordanCT and CalviLM. (2009). In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood, 114:4054–4063.
32.
BenezraR, DavisRL, LockshonD, TurnerDL and WeintraubH. (1990). The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell, 61:49–59.
33.
ChenW and Ten DijkeP. (2016). Immunoregulation by members of the TGFbeta superfamily. Nat Rev Immunol, 16:723–740.
34.
UekiY and RehTA. (2012). Activation of BMP-Smad1/5/8 signaling promotes survival of retinal ganglion cells after damage in vivo. PLoS One, 7:e38690.
35.
ViñalsF and VenturaF. (2004). Myogenin protein stability is decreased by BMP-2 through a mechanism implicating Id1. J Biol Chem, 279:45766–45772.
36.
YangJ, LiX, LiY, SouthwoodM, YeL, LongL, Al-LamkiRS and MorrellNW. (2013). Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 305:L312–L321.
37.
LewisTC and PrywesR. (2013). Serum regulation of Id1 expression by a BMP pathway and BMP responsive element. Biochim Biophys Acta, 1829:1147–1159.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
